In nodal T-NHL, RBMX expression was not significantly associated with a poor PFS (RBMXlow vs. RBMXhigh: median OS 16.0 (95% CI: 4.8–27.2) vs. 9.0 (95% CI: 5.6–12.4) months; p = 0.152; Figure 4d). This evidence concerns the gene RBMX and non-Hodgkin lymphoma.